AstraZeneca heads into its Q1 2026 results — due before the London open on April 29 — after a choppy month that has left the stock nursing a 5% weekly loss and sitting near GBP 139.
The lending market offers little indication of anxious short sellers. Short interest is negligible at just 0.13% of the free float, with borrow availability so abundant it is effectively uncapped — the availability-to-short-interest ratio sits at the practical ceiling of 9,999%. Borrowing costs have edged higher over the past month, rising about 15% to 0.70%, but the absolute level remains close to the risk-free rate. With utilisation barely registering below its 52-week high of 1.24%, this is not a stock where short pressure is a meaningful force. The ORTEX short score of 25.8 — ranked in the 96th percentile for low short-seller interest — reinforces that picture. The recent share price drift lower reflects something other than a concentrated short thesis building.
The investor debate heading into this print is squarely about pipeline execution and top-line growth. On the positive side, the FDA approved AZN's Saphnelo for systemic lupus erythematosus just days ahead of the results, and Breztri triple therapy received a new label expansion for adolescent and adult asthma — two incremental pipeline wins that broaden the revenue base. Revenue is estimated near $63 billion for the full year, with EBITDA around $22.4 billion, implying an EV/EBITDA of roughly 13.7x. That is a reasonable valuation for a large-cap pharma growing through a deep drug portfolio, though the P/B of 5.1x and PE of 17.7x leave little room for a guidance miss. The valuation multiples have compressed modestly over the past week — PE slipped about 0.76 turns — consistent with the broader pharma sector selling off. Close peers and were both down around 6% on the week, suggesting the pressure is more sector-wide than -specific.
Institutional ownership tells a constructive long-term story. BlackRock holds nearly 8.9% and added 759,000 shares in the most recent reporting period. Norges Bank Investment Management added over 3.1 million shares, and HSBC Global Asset Management added 2.3 million. Capital Research and Management, a long-standing major holder, added close to 2 million shares. The only notable insider transaction in the trailing 90 days was an award — not a market sale — to CEO Pascal Soriot, leaving the net insider cash position essentially flat. There is no insider selling signal to cloud the picture.
Past earnings reactions have been asymmetric and lopsided to the upside. The February 2026 full-year results triggered a 6.7% single-day gain and an 11.8% move over the following five days. The April 9 event this year produced only a flat 0.09% day-one reaction, suggesting the market has already digested the pipeline narrative and will focus on whether the first-quarter numbers justify the multiple. The print is therefore less a question of whether AZN can grow and more a test of whether the company's guided revenue trajectory holds under the weight of sector-wide valuation pressure and a strong prior comparator.
See the live data behind this article on ORTEX.
Open AZN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
